Stockholm, April 6, 2022 - Intervacc AB (publ) announces that the company's 2021 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is ... Read more
Stockholm, March 23, 2022 - Intervacc announces today that the first batch of Strangvac®, a vaccine against equine Strangles, has been released for sale in Sweden.
“Strangvac® has now ... Read more
Stockholm, March 9, 2022 - The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months.
The period in summary
January 1 – December 31, 2021
- The European Commission granted in August a Marketing ... Read more
Stockholm, February 16, 2022 - Intervacc AB (publ) announces that the Company’s application for a Permit for Sale and Distribution of Strangvac® in the U.S. has been submitted to the U.S. Department of ... Read more
